Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study.

Abstract

BACKGROUND:

Hemorrhagic cystitis (HC) is an inflammatory disease of the bladder with sustained hematuria for which there is currently no approved drug treatment. We evaluated a liposomal tacrolimus preparation (LP-10) in patients with refractory moderate to severe sterile HC.

METHODS:

This phase 2a dose-escalation study assessed the safety and efficacy of up to 2 intravesical instillations of LP-10 (2, 4, or 8 mg tacrolimus) in 13 patients with HC. Primary efficacy outcomes were changes from baseline in the number of bleeding sites on cystoscopy, microscopic urine analysis for red blood cells (RBCs), and hematuria on dipstick. Additional efficacy measures included urinary incontinence, frequency, and urgency on a 3-day diary and cystoscopy global response assessment (GRA). Blood samples for pharmacokinetic (PK) assessment were obtained in all patients.

RESULTS:

Intravesical LP-10 was well tolerated, with no treatment-related severe or serious adverse events (AEs) and only 3 drug-related AEs (artificial urinary sphincter malfunction, dysuria, and bladder spasms). LP-10 blood levels showed short durations of minimal systemic uptake. Treatment resulted in significant improvements in bleeding on cystoscopy, RBC counts in urine, hematuria on dipstick, and urinary incontinence. Bleeding on cystoscopy and urinary incontinence showed dose-dependent improvements that were more pronounced in the 4 mg and 8 mg dose groups. All dose groups showed a significant improvement in cystoscopy GRA.

CONCLUSION:

LP-10 was well tolerated, with clinically relevant efficacy seen in improvements in cystoscopic bleeding, hematuria, and urinary incontinence. The benefit-risk profile supports the further clinical development of LP-10 at a tacrolimus dose of 4 mg.

• Authors: Jason Hafron, Benjamin N Breyer, Shreyas Joshi, Christopher Smith, Melissa R Kaufman, Janet Okonski, Michael B Chancellor
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 56 Issue 1 Pg. 87-96 (Jan 2024) ISSN: 1573-2584 [Electronic] Netherlands
• PMID: 37725274 (Publication Type: Clinical Trial, Phase II, Multicenter Study)
• Copyright: © 2023. The Author(s).

Chemical References

• Tacrolimus

Topics

• Humans
• Administration, Intravesical
• Cystitis (drug therapy)
• Cystitis, Hemorrhagic
• Hematuria (drug therapy, etiology)
• Hemorrhage (etiology)
• Tacrolimus (therapeutic use)
• Urinary Bladder
• Urinary Incontinence